D
Dare Bioscience Inc (DARE)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
$0.58
-0.07 (-11.13%)
Market Cap: $12.93M
Last updated: Nov 17, 2026 at 11:03 AM ET
Dare Bioscience Inc (DARE) Valuation Multiples
Dare Bioscience (DARE) trades at 6.4x sales. Its forward P/E is 1.3x.
Current Multiples
| Multiple | Value |
|---|---|
| P/E (trailing) | N/A |
| Forward P/E | 1.3x |
| Price to sales | 6.4x |
| EV/FCF | 0.3x |
| PEG | N/A |
| FCF yield | -135.1% |
Valuation History
Over the 6 of the 10 year ends shown that have a P/B, its P/B ranged from 2.7x in 2021 to 33.6x in 2019.
| Year end | Price | P/S | P/B |
|---|---|---|---|
| 2025 | $1.93 | 28.2x | 9.8x |
| 2024 | $3.12 | N/A | N/A |
| 2023 | $3.71 | 9.8x | N/A |
| 2022 | $9.96 | N/A | 6.1x |
| 2021 | $24.01 | N/A | 2.7x |
| 2020 | $16.09 | N/A | N/A |
| 2019 | $9.84 | N/A | 33.6x |
| 2018 | $8.53 | N/A | 14.5x |
| 2017 | $25.98 | N/A | 5.8x |
| 2016 | $85.02 | N/A | N/A |
GNG Valuation
| GNG view | Undervalued |
|---|
GNG fair value is part of GNG Pro. See plans
Frequently Asked Questions About DARE
What is DARE's forward P/E ratio?
Dare Bioscience has a forward P/E ratio of 1.3x.
Is DARE stock overvalued?
GNG's valuation label for DARE is Undervalued.
What is DARE's price to sales ratio?
Dare Bioscience has a price to sales ratio of 6.4x.
DARE pages: Overview, Earnings, Forecast, Financials, Valuation, Competitors